These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33330842)

  • 41. [Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection].
    Troldborg A; Bartels LE; Deleuran B
    Ugeskr Laeger; 2020 May; 182(20):. PubMed ID: 32400380
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery of new drug indications for COVID-19: A drug repurposing approach.
    Kumari P; Pradhan B; Koromina M; Patrinos GP; Steen KV
    PLoS One; 2022; 17(5):e0267095. PubMed ID: 35609015
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and
    Banerjee S; Yadav S; Banerjee S; Fakayode SO; Parvathareddy J; Reichard W; Surendranathan S; Mahmud F; Whatcott R; Thammathong J; Meibohm B; Miller DD; Jonsson CB; Dubey KD
    J Chem Inf Model; 2021 Nov; 61(11):5469-5483. PubMed ID: 34666487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An
    Behera SK; Mahapatra N; Tripathy CS; Pati S
    Indian J Med Res; 2021 Jan & Feb; 153(1 & 2):132-143. PubMed ID: 33818470
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cyanorona-20: The first potent anti-SARS-CoV-2 agent.
    Rabie AM
    Int Immunopharmacol; 2021 Sep; 98():107831. PubMed ID: 34247016
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection.
    Klimke A; Hefner G; Will B; Voss U
    Med Hypotheses; 2020 Sep; 142():109783. PubMed ID: 32402766
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines.
    Awadasseid A; Wu Y; Tanaka Y; Zhang W
    Biomed Pharmacother; 2021 May; 137():111330. PubMed ID: 33550043
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges.
    Yang X; Liu Y; Liu Y; Yang Q; Wu X; Huang X; Liu H; Cai W; Ma G
    Expert Rev Clin Pharmacol; 2020 Sep; 13(9):957-975. PubMed ID: 32746653
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Scoping insight on antiviral drugs against COVID-19.
    Ali AS; Ibrahim IM; Burzangi AS; Ghoneim RH; Aljohani HS; Alsamhan HA; Barakat J
    Arab J Chem; 2021 Oct; 14(10):103385. PubMed ID: 34909060
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Investigation of Some Antiviral
    Hagar M; Ahmed HA; Aljohani G; Alhaddad OA
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486229
    [TBL] [Abstract][Full Text] [Related]  

  • 54. COVID-19: Are Experimental Drugs a Cure or Cause?
    Karahalil B; Elkama A
    Curr Drug Saf; 2022; 17(2):83-89. PubMed ID: 34315382
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
    Shahbazi B; Mafakher L; Teimoori-Toolabi L
    J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
    Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
    Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
    Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
    mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Computational investigation of binding of chloroquinone and hydroxychloroquinone against PLPro of SARS-CoV-2.
    Patel D; Athar M; Jha PC
    J Biomol Struct Dyn; 2022 Apr; 40(7):3071-3081. PubMed ID: 33200683
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacophore screening to identify natural origin compounds to target RNA-dependent RNA polymerase (RdRp) of SARS-CoV2.
    Mishra A; Rathore AS
    Mol Divers; 2022 Oct; 26(5):2613-2629. PubMed ID: 35000060
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
    Mehta S; Bhandari S; Mehta S
    J Glob Antimicrob Resist; 2020 Sep; 22():864-865. PubMed ID: 32777441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.